These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21452309)

  • 1. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
    Bendtzen K
    Arthritis Rheum; 2011 Apr; 63(4):867-70. PubMed ID: 21452309
    [No Abstract]   [Full Text] [Related]  

  • 2. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.
    Korswagen LA; Bartelds GM; Krieckaert CL; Turkstra F; Nurmohamed MT; van Schaardenburg D; Wijbrandts CA; Tak PP; Lems WF; Dijkmans BA; van Vugt RM; Wolbink GJ
    Arthritis Rheum; 2011 Apr; 63(4):877-83. PubMed ID: 21452312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment.
    Bartelds GM; Wolbink GJ; Stapel S; Aarden L; Lems WF; Dijkmans BA; Nurmohamed MT
    Ann Rheum Dis; 2006 Sep; 65(9):1249-50. PubMed ID: 16905585
    [No Abstract]   [Full Text] [Related]  

  • 4. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner.
    Krieckaert CL; Nurmohamed MT; Wolbink GJ
    Ann Rheum Dis; 2012 Nov; 71(11):1914-5. PubMed ID: 22586169
    [No Abstract]   [Full Text] [Related]  

  • 5. Adalimumab for rheumatoid arthritis?
    Ebell M; Kripke C
    Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
    [No Abstract]   [Full Text] [Related]  

  • 6. Rheumatoid arthritis.
    Burchini G; Orsi C
    N Engl J Med; 2004 Sep; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
    [No Abstract]   [Full Text] [Related]  

  • 7. New drugs for rheumatoid arthritis.
    Messori A; Santarlasci B; Vaiani M
    N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option.
    Abadoglu O; Epozturk K; Atayik E; Kaptanoglu E
    J Investig Allergol Clin Immunol; 2011; 21(4):319-21. PubMed ID: 21721382
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
    Strangfeld A; Hierse F; Kekow J; von Hinueber U; Tony HP; Dockhorn R; Listing J; Zink A
    Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab in juvenile rheumatoid arthritis.
    Taddio A; Marchetti F
    N Engl J Med; 2008 Dec; 359(23):2495-6; author reply 2496-7. PubMed ID: 19065749
    [No Abstract]   [Full Text] [Related]  

  • 12. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
    Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
    J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL; Silman AJ
    J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
    [No Abstract]   [Full Text] [Related]  

  • 14. The 'alphabet' of rheumatoid arthritis treatment.
    Capriotti T
    Medsurg Nurs; 2004 Dec; 13(6):420-8. PubMed ID: 15714747
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
    Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
    Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic nocardiosis in a case of rheumatoid arthritis treated with tumor necrosis factor blockers.
    Wendling D; Murad M; Mathieu S; Berger E; Rumbach L
    J Rheumatol; 2008 Mar; 35(3):539-42. PubMed ID: 18322977
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic listeriosis with adalimumab therapy.
    Murphy G; Schmidt-Martin D; Hynes BG; Harney S
    J Clin Rheumatol; 2009 Oct; 15(7):369-70. PubMed ID: 20009978
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.